Aurora Cannabis Inc (ACB) is a major Canadian cannabis producer operating across five continents. On February 11, 2019, ACB reported earnings for the quarter ending December 31, 2018. The company noted with earnings that it currently had “40 clinical trials and case studies completed or in progress,” an achievement which forms part of the bull case on ACB. In this article I look into those clinical studies to see if there is indeed something to get excited about for ACB bulls or if these trials just represent filler material.
What trials is ACB running?
When we look into ACB’s corporate slide deck, we do find a slide covering a selection of clinical trials but the actual details provided are quite minimal.
Figure 1: ACB